Comparing Between CO2 and Phenylephrine Treatment in Patients With Progressive Lacunar Infarction (CARBOGEN Study)
Key facts
- Who runs it
- Yonsei University
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 3 people enrolled
- Started
- 5 Apr 2021
- Ended
- 12 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- carbogen
- phenylephrine
- Record updated
- 14 January 2025
- Why it stopped
- Slow Patient Enrollment
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Age ≥20 years
- Anterior circulation progressive lacunar infarction
- Neurological worsening either 1 point in NIHSS score or MRC grade
Who cannot take part
- Moyamoya disease
- Difficulty in inhalation of Carbogen (panic, severe anxiety disorder)
- Drug allergy for phenylephrine
- History of hemorrhagic stroke
- Pre-stroke mRS ≥2
- Age <20
- Cortical infarction
- Posterior circulation lacunar infarction
- Relevant artery stenosis more than 50% or occlusion
- Persistent bradycardia (pulse rate < 50 /min)
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Lacunar infarction is an ischemic stroke occurred by small perforating artery occlusion . Twenty percent of ischemic stroke is lacunar infarction.
Read full original descriptionShow less
However, outcome of lacunar infarction is excellent, about 20-40% patients are suffered neurological worsening.
Progressive lacunar infarction is associated poor functional outcome and neurological deficit.
Currently, no treatment for progressive lacunar infarction is recommended on the guideline.
Several small study reported that phenylephrine and magnesium may be helpful for progressive lacunar infarction.
Carbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the treatment of sudden sensory neural hearing loss or ocular ischemia.
CO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood flow.
Lacunar infarction is small and perfused with marginal flow by neighboring perforating arteriole.
Increased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and revert progressive lacunar infarction.
Induced hypertension is alternative treatment of progressive lacunar infarction. Increasing blood pressure also induce cerebral blood flow.
Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on cerebral artery or heart.
Several studies reported that the effectiveness of phenylephrine on progressing stroke.
Therefore, this study will compare the effectiveness of carbogen versus phenylephrine in lacunar infarction patients who suffered neurological worsening.
The 2 groups in the trial
- Carbogen groupTreatment being tested
Treatment: carbogen
- Phenylephrine groupExisting treatment, for comparison
Treatment: phenylephrine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 14 January 2025